Major Highlights of the CAR-TCR Summit, Boston, 2016

Author(s): Vita Golubovskaya*, Robert Berahovich, Shirley Xu, Hizkia Harto, Lijun Wu*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 17 , Issue 10 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Cellular immunotherapies such as CAR-T cell therapy and TCR-T cell therapy are relatively new, highly promising approaches for the treatment of cancer. In CAR-T cell therapy, a patient's T cells are engineered to express chimeric antigen receptors targeting tumor-associated cell surface antigens. In TCR-T cell therapy, the patient's T cells are engineered to express receptors targeting intracellular antigens. This report will summarize presentations from the recent CAR-TCR summit in Boston on September 13-16, 2016. These presentations were given by leaders in the field and many were divided into three streams: Discovery and Genetic T Cell Engineering; Translation and Clinical Development; and Manufacturing, Supply Chain and Commercialization. The report summarizes major pharmaceutical companies developing these novel therapies and provides challenges and perspectives for future therapeutic developments.

Keywords: Chimeric antigen receptor, immunotherapy, cytokine, cancer, tumor antigen, T-cell enginering.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1344 - 1350]
Pages: 7
DOI: 10.2174/1871520617666170110151900
Price: $65

Article Metrics

PDF: 63